Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

BACKGROUND: Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment. It remains unclear why myelomas are peculiarly sensitive to bortezomib, or what...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ling, Silvia C. W., Lau, Edwin K. K., Al-Shabeeb, Ammira, Nikolic, Angela, Catalano, Albert, Iland, Harry, Horvath, Noemi, Ho, P. Joy, Harrison, Simon, Fleming, Shaun, Joshua, Douglas E., Allen, John D.
Формат: Artigo
Язык:Inglês
Опубликовано: Ferrata Storti Foundation 2012
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3248932/
https://ncbi.nlm.nih.gov/pubmed/21993678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.043331
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы